Back to Authors

Ma, Yuju

A5102213306 | I4210139373

Mayo Clinic

Teva Pharmaceuticals (United States)

Citations 6

Efficacy of Two Dose Regimens of Subcutaneous Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (S32.005)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.s32.005

Efficacy Of Fremanezumab in Patients With Chronic Migraine With or Without Concomitant Use of Preventive Medication (P4.099)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.099

Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.093)

Neurology | December 7, 2023 | Volume: 90 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.90.15_supplement.p4.093

Fremanezumab for preventive treatment of migraine

Neurology | August 17, 2018 | Volume: 91 | Issue: 12 | Pages: No page available

10.1212/01.wnl.0000544321.19316.40 | PMID 30120138

Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine

JAMA | May 17, 2018 | Volume: 319 | Issue: 19 | Pages: 1999

10.1001/jama.2018.4853 | PMID 29800211

TEV-48125 for the preventive treatment of chronic migraine

Neurology | June 9, 2016 | Volume: 87 | Issue: 1 | Pages: 41-48

10.1212/wnl.0000000000002801 | PMID 27281531